Aerpio Pharmaceuticals, Inc. (ARPO)
| Market Cap | 60.77M |
| Revenue (ttm) | 15.00M |
| Net Income (ttm) | -4.04M |
| Shares Out | 42.14M |
| EPS (ttm) | -0.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 27 |
| Last Price | $1.22 |
| Previous Close | $1.30 |
| Change ($) | -0.08 |
| Change (%) | -6.15% |
| Day's Open | 1.25 |
| Day's Range | 1.21 - 1.28 |
| Day's Volume | 1,453,488 |
| 52-Week Range | 0.45 - 2.25 |
Aerpio (ARPO) unveils strategic alternatives after it announced top-line results from a phase II study of razuprotafib in glaucoma patients in December.
Aerpio Pharmaceuticals (ARPO) has been struggling lately, but the selling pressure may be coming to an end soon.
CINCINNATI, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate...
Does Aerpio Pharmaceuticals, Inc. (ARPO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-sp...
Primary endpoint achieved with twice-daily dose group at 28 day time point versus latanoprost control group.
Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors.
Aerpio Pharmaceuticals, Inc. (ARPO) Management on Q3 2020 Results - Earnings Call Transcript
Conference Call Today, November 10 , 2020 at 8:30 a.m. EST
CINCINNATI, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat oc...
Call Taking Place on Thursday, November 12th @ 11amET Call Taking Place on Thursday, November 12th @ 11amET
The trial in moderate-to-severe patients is Aerpio's second clinical trial in COVID-19 patients and is funded in part by the U . S . military
Topline Data Expected 4Q 2020 Topline Data Expected 4Q 2020
SAN FRANCISCO and CINCINNATI, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced to...
Aerpio Pharmaceuticals' (ARPO) Management on Q2 2020 Results - Earnings Call Transcript
Conference Call Today, August 12, 2020 at 8:30 a.m. EDT
CINCINNATI, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ...
CINCINNATI, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and The U.S. Government operating through the Medical Technology Enterprise Consortium (M...
In the latest trading session, Aerpio Pharmaceuticals, Inc. (ARPO) closed at $1.26, marking a +1.61% move from the previous day.
Is (ARPO) Outperforming Other Medical Stocks This Year?
As of late, it has definitely been a great time to be an investor in Aerpio Pharmaceuticals.
Aerpio Pharmaceuticals, Inc. (ARPO) closed the most recent trading day at $1.25, moving +0.81% from the previous trading session.
Is (ARPO) Outperforming Other Medical Stocks This Year?
CINCINNATI, June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ARPO), today announced that, due to the public health and safety concerns related to the n...
CINCINNATI, June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ...
SAN FRANCISCO and CINCINNATI, May 27, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced toda...
SAN FRANCISCO and CINCINNATI, May 27, 2020 /PRNewswire/ -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an a...
Aerpio Pharmaceuticals, Inc. (ARPO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
Aerpio Received an Immediate Payment of $15 million Aerpio Received an Immediate Payment of $15 million
Aerpio Pharmaceuticals, Inc. (ARPO) closed at $0.72 in the latest trading session, marking a +0.61% move from the prior day.
Is (ARPO) Outperforming Other Medical Stocks This Year?
Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Aerpio Pharmaceuticals, Inc. (ARPO) on Q4 2019 Results - Earnings Call Transcript
Our year-end roundtable rolls into 2020 with a look at small-cap investing.
Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Shares of Aerpio Pharmaceuticals Inc. plummeted 71% toward a record low in active trade Monday, after the biopharmaceutical company said a phase 2b study of its treatment for diabetic retinopa...
About ARPO
Aerpio Pharmaceuticals, a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company's lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; GB004, a selective stabilizer of hyp... [Read more...]
| Industry Biotechnology | |
| Stock Exchange NASDAQ | Ticker Symbol ARPO |
Analyst Forecasts
According to 2 analysts, the average rating for ARPO stock is "Buy." The 12-month stock price forecast is 1.75, which is an increase of 43.44% from the latest price.